Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma

Corrine K. Welt, Geralyn Lambert-Messerlian, Wenxin - Zheng, William F. Crowley, Alan L. Schneyer

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Activin induces proliferation in epithelial ovarian carcinoma cell lines, whereas follistatin (FS), an activin binding protein, inhibits this action. To test the hypothesis that activin production, in excess of inhibin and FS, results in cell proliferation in epithelial ovarian tumors, messenger RNA (mRNA) expression of the activin family of proteins, FS, and activin type I and II receptors was examined in 25 primary epithelial ovarian tumors and tumor epithelium in culture (n = 7) using RT-PCR. Activin A was measured in the serum of ovarian cancer patients, and activin A, total inhibin, and FS protein secretion was measured from primary epithelial tumors in vitro. The effect of activin and FS on cell proliferation was assessed by measuring [3H]thymidine incorporation. All results were compared with normal ovarian epithelium. All epithelial ovarian tumors expressed mRNA for the α, βA, and βB subunits; FS 288 and 315; and the activin type IA, IB, II, and IIB receptors. βA mRNA expression, as assessed using semiquantitative RT-PCR, was 3-fold greater in cultured tumor epithelium than in primary tumors (band density 0.86 ± 0.17 vs. 0.28 ± 0.09; P < 0.01). In addition, βA mRNA was abundantly expressed in normal epithelium in culture (n = 2), whereas only trace amounts were seen in 2/9 primary epithelial samples. Activin protein was secreted by 24/25 primary epithelial ovarian tumors (range 0.2-155.8 ng/mL). In contrast, total inhibin was secreted by only 2/25 (range 0.01- 0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (<0.5 ng/mL). Treatment with activin or FS did not consistently affect cell growth. Measurement of serum activin A in a subset of subjects and in 27 additional subjects with epithelial ovarian carcinoma (n = 33) revealed preoperative activin A levels >3 SD above the mean for pro- and postmenopausal women in 13/33 (39%) subjects. We conclude that in epithelial ovarian cancer: 1) βA subunit mRNA is expressed, 2) activin protein is secreted more frequently than inhibin and in greater quantities than FS, 3) βA subunit mRNA expression is greater in neoplastic and normal epithelium in culture than in the primary tissue, 4) the majority of tumors in culture do not respond to activin or FS treatment with proliferation, and 5) serum activin levels may reflect tumor secretion in some patients. Thus, activin A appears to be available as an autocrine/paracrine factor in epithelial ovarian tumors and may contribute to circulating levels, but its role in tumorigenesis has yet to be defined.

Original languageEnglish (US)
Pages (from-to)3720-3727
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume82
Issue number11
StatePublished - 1997
Externally publishedYes

Fingerprint

Follistatin
Activins
Inhibins
Tumors
Carcinoma
Neoplasms
Epithelium
Messenger RNA
Cell proliferation
Type I Activin Receptors
Type II Activin Receptors
Cell Proliferation
Polymerase Chain Reaction
Proteins
Serum
Ovarian Neoplasms
Thymidine
Carcinogenesis
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Welt, C. K., Lambert-Messerlian, G., Zheng, W. ., Crowley, W. F., & Schneyer, A. L. (1997). Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. Journal of Clinical Endocrinology and Metabolism, 82(11), 3720-3727.

Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. / Welt, Corrine K.; Lambert-Messerlian, Geralyn; Zheng, Wenxin -; Crowley, William F.; Schneyer, Alan L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 11, 1997, p. 3720-3727.

Research output: Contribution to journalArticle

Welt, CK, Lambert-Messerlian, G, Zheng, W, Crowley, WF & Schneyer, AL 1997, 'Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma', Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 11, pp. 3720-3727.
Welt, Corrine K. ; Lambert-Messerlian, Geralyn ; Zheng, Wenxin - ; Crowley, William F. ; Schneyer, Alan L. / Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. In: Journal of Clinical Endocrinology and Metabolism. 1997 ; Vol. 82, No. 11. pp. 3720-3727.
@article{5afd48196dfa4c829ba3a45d05a3025c,
title = "Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma",
abstract = "Activin induces proliferation in epithelial ovarian carcinoma cell lines, whereas follistatin (FS), an activin binding protein, inhibits this action. To test the hypothesis that activin production, in excess of inhibin and FS, results in cell proliferation in epithelial ovarian tumors, messenger RNA (mRNA) expression of the activin family of proteins, FS, and activin type I and II receptors was examined in 25 primary epithelial ovarian tumors and tumor epithelium in culture (n = 7) using RT-PCR. Activin A was measured in the serum of ovarian cancer patients, and activin A, total inhibin, and FS protein secretion was measured from primary epithelial tumors in vitro. The effect of activin and FS on cell proliferation was assessed by measuring [3H]thymidine incorporation. All results were compared with normal ovarian epithelium. All epithelial ovarian tumors expressed mRNA for the α, βA, and βB subunits; FS 288 and 315; and the activin type IA, IB, II, and IIB receptors. βA mRNA expression, as assessed using semiquantitative RT-PCR, was 3-fold greater in cultured tumor epithelium than in primary tumors (band density 0.86 ± 0.17 vs. 0.28 ± 0.09; P < 0.01). In addition, βA mRNA was abundantly expressed in normal epithelium in culture (n = 2), whereas only trace amounts were seen in 2/9 primary epithelial samples. Activin protein was secreted by 24/25 primary epithelial ovarian tumors (range 0.2-155.8 ng/mL). In contrast, total inhibin was secreted by only 2/25 (range 0.01- 0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (<0.5 ng/mL). Treatment with activin or FS did not consistently affect cell growth. Measurement of serum activin A in a subset of subjects and in 27 additional subjects with epithelial ovarian carcinoma (n = 33) revealed preoperative activin A levels >3 SD above the mean for pro- and postmenopausal women in 13/33 (39{\%}) subjects. We conclude that in epithelial ovarian cancer: 1) βA subunit mRNA is expressed, 2) activin protein is secreted more frequently than inhibin and in greater quantities than FS, 3) βA subunit mRNA expression is greater in neoplastic and normal epithelium in culture than in the primary tissue, 4) the majority of tumors in culture do not respond to activin or FS treatment with proliferation, and 5) serum activin levels may reflect tumor secretion in some patients. Thus, activin A appears to be available as an autocrine/paracrine factor in epithelial ovarian tumors and may contribute to circulating levels, but its role in tumorigenesis has yet to be defined.",
author = "Welt, {Corrine K.} and Geralyn Lambert-Messerlian and Zheng, {Wenxin -} and Crowley, {William F.} and Schneyer, {Alan L.}",
year = "1997",
language = "English (US)",
volume = "82",
pages = "3720--3727",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma

AU - Welt, Corrine K.

AU - Lambert-Messerlian, Geralyn

AU - Zheng, Wenxin -

AU - Crowley, William F.

AU - Schneyer, Alan L.

PY - 1997

Y1 - 1997

N2 - Activin induces proliferation in epithelial ovarian carcinoma cell lines, whereas follistatin (FS), an activin binding protein, inhibits this action. To test the hypothesis that activin production, in excess of inhibin and FS, results in cell proliferation in epithelial ovarian tumors, messenger RNA (mRNA) expression of the activin family of proteins, FS, and activin type I and II receptors was examined in 25 primary epithelial ovarian tumors and tumor epithelium in culture (n = 7) using RT-PCR. Activin A was measured in the serum of ovarian cancer patients, and activin A, total inhibin, and FS protein secretion was measured from primary epithelial tumors in vitro. The effect of activin and FS on cell proliferation was assessed by measuring [3H]thymidine incorporation. All results were compared with normal ovarian epithelium. All epithelial ovarian tumors expressed mRNA for the α, βA, and βB subunits; FS 288 and 315; and the activin type IA, IB, II, and IIB receptors. βA mRNA expression, as assessed using semiquantitative RT-PCR, was 3-fold greater in cultured tumor epithelium than in primary tumors (band density 0.86 ± 0.17 vs. 0.28 ± 0.09; P < 0.01). In addition, βA mRNA was abundantly expressed in normal epithelium in culture (n = 2), whereas only trace amounts were seen in 2/9 primary epithelial samples. Activin protein was secreted by 24/25 primary epithelial ovarian tumors (range 0.2-155.8 ng/mL). In contrast, total inhibin was secreted by only 2/25 (range 0.01- 0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (<0.5 ng/mL). Treatment with activin or FS did not consistently affect cell growth. Measurement of serum activin A in a subset of subjects and in 27 additional subjects with epithelial ovarian carcinoma (n = 33) revealed preoperative activin A levels >3 SD above the mean for pro- and postmenopausal women in 13/33 (39%) subjects. We conclude that in epithelial ovarian cancer: 1) βA subunit mRNA is expressed, 2) activin protein is secreted more frequently than inhibin and in greater quantities than FS, 3) βA subunit mRNA expression is greater in neoplastic and normal epithelium in culture than in the primary tissue, 4) the majority of tumors in culture do not respond to activin or FS treatment with proliferation, and 5) serum activin levels may reflect tumor secretion in some patients. Thus, activin A appears to be available as an autocrine/paracrine factor in epithelial ovarian tumors and may contribute to circulating levels, but its role in tumorigenesis has yet to be defined.

AB - Activin induces proliferation in epithelial ovarian carcinoma cell lines, whereas follistatin (FS), an activin binding protein, inhibits this action. To test the hypothesis that activin production, in excess of inhibin and FS, results in cell proliferation in epithelial ovarian tumors, messenger RNA (mRNA) expression of the activin family of proteins, FS, and activin type I and II receptors was examined in 25 primary epithelial ovarian tumors and tumor epithelium in culture (n = 7) using RT-PCR. Activin A was measured in the serum of ovarian cancer patients, and activin A, total inhibin, and FS protein secretion was measured from primary epithelial tumors in vitro. The effect of activin and FS on cell proliferation was assessed by measuring [3H]thymidine incorporation. All results were compared with normal ovarian epithelium. All epithelial ovarian tumors expressed mRNA for the α, βA, and βB subunits; FS 288 and 315; and the activin type IA, IB, II, and IIB receptors. βA mRNA expression, as assessed using semiquantitative RT-PCR, was 3-fold greater in cultured tumor epithelium than in primary tumors (band density 0.86 ± 0.17 vs. 0.28 ± 0.09; P < 0.01). In addition, βA mRNA was abundantly expressed in normal epithelium in culture (n = 2), whereas only trace amounts were seen in 2/9 primary epithelial samples. Activin protein was secreted by 24/25 primary epithelial ovarian tumors (range 0.2-155.8 ng/mL). In contrast, total inhibin was secreted by only 2/25 (range 0.01- 0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (<0.5 ng/mL). Treatment with activin or FS did not consistently affect cell growth. Measurement of serum activin A in a subset of subjects and in 27 additional subjects with epithelial ovarian carcinoma (n = 33) revealed preoperative activin A levels >3 SD above the mean for pro- and postmenopausal women in 13/33 (39%) subjects. We conclude that in epithelial ovarian cancer: 1) βA subunit mRNA is expressed, 2) activin protein is secreted more frequently than inhibin and in greater quantities than FS, 3) βA subunit mRNA expression is greater in neoplastic and normal epithelium in culture than in the primary tissue, 4) the majority of tumors in culture do not respond to activin or FS treatment with proliferation, and 5) serum activin levels may reflect tumor secretion in some patients. Thus, activin A appears to be available as an autocrine/paracrine factor in epithelial ovarian tumors and may contribute to circulating levels, but its role in tumorigenesis has yet to be defined.

UR - http://www.scopus.com/inward/record.url?scp=0030670883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030670883&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 3720

EP - 3727

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -